
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
For the past few months, I have been a part of an arbitration panel of physicians, hired by an organization that gives independent opinions concerning claims for reimbursement for medical providers, pre-authorization issues and quality of care issues.